Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?
This plain language summary provides an overview of a real-world study using data from the Veterans Health Administration to look at the survival of Black men vs White men with advanced prostate cancer who are treated with two treatments, abiraterone or enzalutamide.
Read the full article here.
The original article on which this summary is based is called ‘Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer’ and was originally published in the journal Prostate Cancer and Prostatic Diseases . The original article can be read here.